Naegis Pharmaceuticals Inc. is a Canadian biopharmaceutical company developing novel, small molecules for the treatment of serious inflammatory diseases.Chronic inflammatory disease represents an enormous societal and economic burden, particularly in an aging population, impacting both quality and quantity of life. Naegis Pharmaceuticals Inc. isdriven to discover new therapies that target underlying chronic inflammatory processes in disease. The Naegis research team seeks to design new drugs that offer safer and more effective treatment options for patients, focusing first on serious eye conditions that result in damage to the back of the eye, with a program directed towards blocking the synthesis of pro-inflammatory mediators in disease.

Biotechnology

Health Care

Pharmaceutical

Therapeutics

Naegis Pharmaceuticals

Naegis Pharmaceuticals' headquarters in Vancouver, Canada

David Burgoyne

Ian Mcbeath

John Langlands

Tim Fernback

Peter Hnik

Julian Gangolli

Glenn Jaffe

David Saperstein

Philip Davies

Cameron Groome

Alan Weiner

Julia Levy

Michael Liggett

The Clinical and Research Advisors team at Naegis Pharmaceuticals plays a critical role in guiding the development of novel therapies for chronic inflammatory diseases. Comprising experts in clinical research, finance, and various scientific disciplines, the team collaborates to ensure that drug development aligns with regulatory standards and clinical efficacy. They provide strategic insights and support for pre-clinical and clinical trials, helping to translate innovative research into safe and effective treatment options for patients, particularly those suffering from serious eye conditions.

Clinical and Research Advisors

Naegis Pharmaceuticals

Org chart

Board & advisors

Teams

Clinical and Research Advisors

Offices

Naegis Pharmaceuticals

Org chart

Board & advisors

Teams

Clinical and Research Advisors

Offices

Related companies